explore the potential of pharmacological reactivation of mutant p53 in cancer treatment, showing that it effectively induces tumor regression and extends survival by restoring classic p53 tumor-suppressive functions and activating immune responses in mice, offering insights for tumor suppressor-based cancer immunotherapy. This evidence concerns the gene TP53 and neoplasm.